My lab primarily works with mouse models, and we frequently use gene knock-out mice and retroviral models of leukemogenesis. Studies to better understand the conditions that foster the initiation of leukemias and lymphomas are currently a major thrust of the lab. In particular, we are investigating how conditions of stress (such as those that impair DNA replication) promote the competitive expansion of cells expressing particular oncogenes, and the mechanism whereby these oncogenes can improve cell cycle progression and survival under conditions of stress. We are exploring how reduced progenitor cellular fitness resulting from carcinogen exposure, inadequate diet or aging can select for adaptive oncogenic events and thereby promote the expansion and fixation of oncogenically initiated cells. While current views of carcinogenesis focus on oncogenic mutations as the limiting step, our studies support a novel rationale for links between tumorigenesis and carcinogenic contexts: these contexts may promote the clonal expansion of cells bearing particular initiating events, in part by reducing progenitor pool fitness which selects for adaptive oncogenic mutations.
Other studies in the lab are geared towards the development of novel therapeutic strategies to treat leukemias. We perform genome-wide loss-of-function screens using RNA interference (RNAi) to identify genes whose inhibition will synergize with current targeted therapeutics to eliminate leukemic cells. Our screens have identified a number of genes that synergistically inhibit chronic myelogenous leukemia cells in combination with the drug imatinib mesylate, and these genes have been validated as therapeutic targets by using both pharmacological and genetic approaches. These studies could lead to discovery of adjuvants to current therapies that will more effectively treat or possibly even cure common blood malignancies. Finally, other studies in the lab are testing whether yeast-based immunotherapies targeting drug resistance mutations can effectively prevent the development of drug resistant leukemias.
Selected Publications
Li, F.X., J.Z. Zhu, C. Hogan and J. DeGregori (2003). Defective gene expression, S phase progression and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol. Cell. Biol., 23, 3607-3622.
Li, F.X., J.W. Zhu, J. Tessem, J. Beilke, M. Varella-Garcia, J. Jensen, C. J. Hogan and J. DeGregori (2003). The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow derived cells in preventing islet cell loss. Proc. Natl. Acad. Sci. USA 100, 12935-12940.
Bilousova G., A. Marusyk, C. Porter, R. Cardiff and J. DeGregori (2005). Impaired DNA replication in progenitor cell pools promotes leukemogenesis. PLoS Biology, 3(12):e401.
Shapiro, G., C. Van Peursem, D. Ornelles, J. Schaack, and J. DeGregori (2006) Recombinant adenoviral vectors can induce the expression of p73 via the E4-orf6/7 protein. J. Virology, 80:5349-60.
Marusyk, A, L. Wheeler, C. Mathews and J. DeGregori (2007). p53 mediates senescence-like arrest induced by chronic replicational stress. Mol. Cell. Biol. 27, 5336-5351. PMID: 17515610
Marusyk, A. and J. DeGregori (2007). Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations (theory paper). BBA Reviews on Cancer 1785: 1-11.
Tessem, J.S., J.N. Jensen, H. Pelli, X-M. Dai, X-H. Zong, E.R. Stanley, J. Jensen, and J. DeGregori (2008). Critical roles for macrophages in islet angiogenesis and maintenance during pancreatic degeneration. Diabetes, 57:1605-17.
CU Faculty PubMed Publications |
|
All PubMed Publications |
Click the link below to go to the Immunology homepage.
http://www.uchsc.edu/immuno/
Back to Top
